Selected Publications (*Corresponding author): (H-index: 21, i10-index: 27)

• Shayantani Chakraborty, Dibyendu Mallick, Mausumi Goswami, F Peter Guengerich, Anindita Chakrabarty*, and Goutam Chowdhury*. The Natural Products Withaferin A and Withanone from the Medicinal Herb Withania somnifera are Covalent Inhibitors of the SARS-CoV-2 Main Protease. J Nat. Prodt. 2022, 85(10), 2340-2350 Front cover page article (Citation 7)

• Anindita Chakrabarty*, Shayantani Chakraborty, Ranjini Bhattacharya, Goutam Chowdhury. Senescence-induced chemoresistance in triple negative breast cancer and evolution-based treatment strategies. Front. Oncol. https://doi.org/10.3389/fonc.2021.674354 Invited Review (Citation 16) 
• Shazia Sidddiqui, Nabeel Ahmed, Anindita Chakrabarty, Goutam Chowdhury. DNA Damage by Withanone as a Potential Cause of Liver Toxicity Observed for Herbal Products of Withania somnifera (Ashwagandha). Curr. Res. Toxicol. 2021, 2, 78-81 (Citation 14) 
• Nabeel Ahmed, Anindita Chakrabarty, F. Peter Guengerich, Goutam Chowdhury. Protective Role of Glutathione against Peroxynitrite-Mediated DNA Damage During Acute Inflammation. Chem. Res. Toxicol. 2020, 33(10) 2668-2674 (Citation 14)
• Tasaduq Hussain Wani, Goutam Chowdhury, Anindita Chakrabarty*. Generation of Reactive Oxygen Species is the Primary Mode of Action and Cause of Survivin Suppression by Sepantronium Bromide. RSC Med. Chem..2021, 12, 566-578 Front Cover Page Article (Citation 2)

• Anindita Chakrabarty*, Sreeraj Surendran, Neil E. Bhola, Vishnu S. Mishra, Tasaduq Husain Wani, Khemraj S. Baghel, Carlos L. Arteaga, Rohini Garg, Goutam Chowdhury. The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells. Carcinogenesis. 2019, 40(10), 1179-1190 Editor’s Choice Article. (Citation 8)
• Wani, TH, Suendran, S, Jana, A, Chakrabarty, A and Chowdhury, G. The Quinone Based Antitumor Agent Sepantronium Bromide (YM155) Causes Oxygen Independent Redox Activated Oxidative DNA Damage. Chem. Res. Toxicol. 2018, 31(7), 612-618 Front Cover Page Article. (Citation 23)

• TH Wani, S Surendran, VS Mishra, J Chaturvedi, G Chowdhury, A Chakrabarty*. Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant, is due to persistent DNA damage-response in breast cancer cells. Oncotarget. 2018, 9 (71), 33589 (Citation 14) 
• Wani, TH, Chakrabarty, A, Shibata, N, Yamazaki, H, Guengerich, FP. and Chowdhury, G. The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage. Chem. Res. Toxicol. 2017, 8, 1622-1628 (Citation 39)

• Chakrabarty, A, Bhola, N, Rinehart, C, Ghosh, R, Kuba, MG, Dave, B, Chang, JC and Arteaga, CL. Trastuzumab-resistant cells continue to rely on a HER2-PI3K-Survivin axis in a FoxO-dependent manner and are sensitive to PI3K inhibitors. Cancer research. 2013, 73(3), 1190-1200 (Citation 127) 

• Chakrabarty, A, Sanchez, V, Kuba, MG, Rinehart, C and Arteaga, CL Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. USA. Breast Cancer Special Feature Article. 2012, 109(8), 2718-2723 (Citation 396)
• Garrett, J, Olivares, M, Rinehart, C, Granja-Ingram, N, Sanchez, V, Chakrabarty, A, Dave, B, Cook, R, Pao, W, McKinely, E, Manning, H, Chang, J and Arteaga, C. Transcriptional and post- translational upregulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. USA.2011, 108(12), 5021-5026 (Citation 489) 
• Garrett, JT, Chakrabarty, A and Arteaga, CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget. 2011, 2(12), 1314-21 (Citation 63) 

• Chakrabarty, A, Rexer, BN, Wang, SE., Cook, RS, Engelman, JA and Arteaga, CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3. Oncogene. 2010, 29(37), 5193-5203 (Citation 108) 

• Chakrabarty, A, Tranguch, S, Daikoku, T, Jensen, K, Furneaux, H and Dey, SK. MicroRNA regulation of Cyclooxygenase-2 during embryo implantation. Proc. Natl. Acad. Sci. USA. 2007, 104, 15144-15149 (Citation 347)

Patent:

• Dana T Aftab, Carlos L Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent. Combinations of kinase inhibitors for the treatment of cancer. US Patent 9011863. 4/21/2015

• Podcast with the ICCA India initiative, 2021 
• Speaker, Emerging Trends in Translational Oncology at AIIMS, Delhi, India, 2020
• Speaker, Virtual Congress on Breast Cancer Research, 2020 
• Speaker, 3rd Translational Cancer Research Symposium at Delhi State Cancer Institute, Delhi India, 2015

• Exploiting the fitness cost of transforming growth factor-β signaling pathway-dependency of chemotherapy-resistant, senescent triple negative breast cancer cells: an evolution-guided therapeutic approach. Anindita Chakrabarty (PI), DST CRG, 2023-2026 (Approved)
• Deciphering the role of the phosphatidylinositol 3-kinase oncogenic mutation in conferring anti-HER2 therapy resistance by enriching for the stem-like tumor initiating cell population in HER2 oncogene-positive breast cancer. Anindita Chakrabarty (PI), DBT Ramalingaswami Re-entry Fellowship, 2014-2019 (Completed)
• Identification of predictive biomarkers of Sepantronium bromide in triple negative breast cancers. Anindita Chakrabarty (PI), DST ECR, 2016-2019 (Completed)
• Elucidating the mechanism of teratogenicity and anti-tumor property of thalidomide. Anindita Chakrabarty (Co-PI), DST ECR, 2016-2019 (Completed)

Combinations of Kinase inhibitors for the treatment of cancer-US9,011,863B2. Date of Patent: April 21, 2015. Inventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron- Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent.

• Frontiers in Oncology: Associate editor.
• BMC Cancer: Associate editor.
• Frontiers in Endocrinology, Frontiers in Medicine: Guest Associate editor.